2seventy bio (TSVT) to Release Earnings on Wednesday

2seventy bio (NASDAQ:TSVT - Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

2seventy bio (NASDAQ:TSVT - Get Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.11. 2seventy bio had a negative return on equity of 59.19% and a negative net margin of 216.73%. The firm had revenue of $10.68 million during the quarter, compared to analyst estimates of $13.91 million. During the same period in the previous year, the company earned ($0.60) EPS. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Stock Down 3.4 %

Shares of TSVT stock traded down $0.17 during trading hours on Friday, reaching $4.76. 598,347 shares of the company's stock were exchanged, compared to its average volume of 1,055,359. 2seventy bio has a fifty-two week low of $1.53 and a fifty-two week high of $12.69. The stock has a market capitalization of $244.66 million, a P/E ratio of -1.08 and a beta of 1.87. The business has a fifty day moving average price of $4.95 and a 200-day moving average price of $4.04.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TSVT. Wedbush reiterated a "neutral" rating and set a $5.00 price target on shares of 2seventy bio in a report on Monday, March 18th. Citigroup upped their price target on 2seventy bio from $9.00 to $12.00 and gave the stock a "buy" rating in a report on Monday, April 8th. TD Cowen reiterated a "market perform" rating on shares of 2seventy bio in a report on Wednesday, January 31st. Leerink Partnrs upgraded 2seventy bio from a "market perform" rating to an "outperform" rating in a report on Wednesday, January 31st. Finally, SVB Leerink upgraded 2seventy bio from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $5.00 to $18.00 in a research report on Wednesday, January 31st. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $13.17.

Insider Activity

In related news, Director Casdin Capital, Llc purchased 330,000 shares of the stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $5.07 per share, for a total transaction of $1,673,100.00. Following the completion of the transaction, the director now directly owns 1,960,000 shares of the company's stock, valued at approximately $9,937,200. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.60% of the stock is currently owned by company insiders.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.